Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.

Pfizer Inc. said Tuesday it has entered a definitive agreement to acquire Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion in cash. Biohaven is the maker of NURTEC ODT, a dual-acting ...

Biohaven common shareholders, including Pfizer, will also receive 0.5 of a share of New Biohaven, a new publicly traded company that will retain Biohaven’s non-CGRP development stage pipeline ...

Pfizer and Biohaven agreed in November to collaborate on selling the two drugs outside the U.S. At the time, Pfizer invested $350 million to acquire 2.6% of Biohaven’s common stock for $173 a share.

Pfizer signed a partnership with Biohaven last November to commercialize Nurtec and zavegepant outside the US. At the time, the firm invested $350 million to acquire a 2.6% stake in Biohaven.

Pfizer will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has a nasal spray under development.

Under the terms of the agreement, Pfizer will acquire all outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in a deal tallying approximately $11.6 billion in cash ...

FILE - A man walks by Pfizer headquarters, Friday, Feb. 5, 2021 in New York. Pfizer is spending more than $11 billion to buy the remaining portion of migraine treatment maker Biohaven ...

Pfizer will acquire all the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, a 78.6% premium to Biohaven's last closing price.

Pfizer first invested in Biohaven last November, according to ABC News. The company will buy all remaining shares at $148.50 per share in cash. 2.

Pfizer will pay $148.50 in cash for each share of Biohaven, which makes Nurtec ODT for treating and preventing migraines and has a nasal spray under development.

Pfizer is starting to put its covid-19 cash influx to use by spending $11.6 billion to venture deeper into a new treatment area. ... Pfizer buying out Biohaven for $11.6B.